SignalPGx Launches White-Label Pharmacogenomics Reporting Platform for CLIA Laboratories

CHICAGO, IL / ACCESS Newswire / August 13, 2026 / SignalPGx LLC today announced the launch of SignalPGx, a global pharmacogenomics reporting and medication intelligence platform built for laboratories, hospital systems, provider networks, clinics, pharmacy partners, and healthcare enterprises.

SignalPGx helps healthcare organizations transform genotype data into clear, evidence-backed medication guidance through white-label PGx reports, physician-reviewed workflows, SignalAI-assisted interpretation, EHR-ready integrations, medication simulation, living reanalysis, and a patient-accessible Living Patient Passport.

Learn more at https://signalpgx.com.

Pharmacogenomics, often referred to as PGx, helps evaluate how a patient’s genetic profile may affect medication response. As laboratories, hospitals, and health systems expand precision medicine programs, healthcare organizations need technology that can turn complex genetic data into medication guidance that is usable across real clinical workflows.

SignalPGx was built to meet that need.

“SignalPGx was built because pharmacogenomics deserves more than a static report,” said Tarek Younis, Founder and CEO of SignalPGx. “Our goal is to help laboratories, hospital systems, and healthcare organizations turn genotype data into living medication intelligence that supports clinical review, EHR integration, patient access, and long-term medication safety.”

At the center of the platform is the SignalPGx Medication Intelligence Graph, an evidence-driven framework that connects pharmacogenomic variants, gene-drug relationships, medication guidance, drug labeling, clinical evidence, and patient-specific medication context. This intelligence layer supports report generation, medication review, SignalAI-assisted interpretation, medication simulation, and reanalysis when evidence or medication profiles change.

SignalPGx currently supports 50+ pharmacogenes and approximately 950 medications with clinical PGx guidance. The platform supports multiple genotype input formats, including VCF, Agena MassARRAY, CSV, and custom laboratory file formats.

SignalPGx incorporates evidence from trusted pharmacogenomic, drug labeling, and clinical reference sources, including CPIC, DPWG, FDA drug labels, PharmGKB, PharmVar, ClinVar, ClinGen, RxNorm, and DailyMed. Each recommendation is designed to support source-aware clinical review and physician decision-making.

Explore the platform at https://signalpgx.com/platform.

A key part of the platform is SignalAI, an AI-assisted clinical interpretation layer that helps summarize evidence, draft source-cited interpretations, support report review, and make PGx findings easier to understand. SignalAI is designed to support clinicians and laboratory teams, not replace medical judgment. Reports remain part of a physician-reviewed workflow before release.

SignalPGx also includes white-label PGx reporting capabilities for laboratories and healthcare organizations that want to deliver branded pharmacogenomics reports under their own identity. Reports can include medication guidance, gene-drug findings, phenotype interpretation, clinical review status, and provider-ready documentation.

Unlike static report generators, SignalPGx is designed as a living medication intelligence platform. A patient’s genotype does not change, but medication history, prescribing decisions, drug labels, clinical guidance, and evidence sources can. SignalPGx is built to support reanalysis, alerts, medication updates, and long-term PGx usability.

SignalPGx also includes a Living Patient Passport, a patient-accessible PGx profile designed to help keep medication intelligence useful beyond the first report.

View the original press release on ACCESS Newswire